Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Ajovy (fremanezumab) a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in 6-17 years patients.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2025
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva’s AJOVY Accepted By FDA For Pediatric Migraine Prevention
Details : Ajovy (fremanezumab) a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in 6-17 years patients.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
April 07, 2025
Details:
Ajovy is a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in adult Chinese patients.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Confirms AJOVY® Efficacy for Migraine Prevention from China Study
Details : Ajovy is a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in adult Chinese patients.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
November 04, 2024
Details:
Ajovy (fremanezumab) a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in 6-17 years patients.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 19, 2024
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Touts First CGRP Success in Phase III Paediatric Migraine Prevention Study
Details : Ajovy (fremanezumab) a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in 6-17 years patients.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
July 19, 2024
Details:
Ajovy (fremanezumab) is a FDA approved mAb which selectively binds the calcitonin gene-related peptide, it is being investigated for episodic migraine in children and adolescents aged 6-17 years.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2024
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Announces Phase 3 Evidence of AJOVY® for Migraine Prevention in Children
Details : Ajovy (fremanezumab) is a FDA approved mAb which selectively binds the calcitonin gene-related peptide, it is being investigated for episodic migraine in children and adolescents aged 6-17 years.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
July 18, 2024
Details:
Ajovy (fremanezumab) is a FDA approved, humanized monoclonal antibody which selectively binds the calcitonin gene-related peptide, it is indicated for preventive treatment of migraine in adults.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Phase IVProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2024
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Details : Ajovy (fremanezumab) is a FDA approved, humanized monoclonal antibody which selectively binds the calcitonin gene-related peptide, it is indicated for preventive treatment of migraine in adults.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2024
Details:
Undisclosed
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody
Sponsor: Teva Pharmaceutical Industries
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2023
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 18, 2023
Details:
Ajovy (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Phase IVProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2023
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Sym...
Details : Ajovy (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
October 17, 2023
Details:
AJOVY (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Phase IVProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 30, 2023
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva’s 3rd Interim Analysis of PEARL Real-world Study on AJOVY (fremanezumab) Reveals Sustained ...
Details : AJOVY (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
June 30, 2023
Details:
AJOVY (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 16, 2022
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injecti...
Details : AJOVY (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
November 16, 2022
Details:
The real-world effectiveness of Ajovy (fremanezumab) in patients with refractory migraine from a US tertiary headache center who switched from erenumab study was also highlighted.
Lead Product(s): Fremanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Ajovy
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2022
Lead Product(s) : Fremanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine...
Details : The real-world effectiveness of Ajovy (fremanezumab) in patients with refractory migraine from a US tertiary headache center who switched from erenumab study was also highlighted.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
September 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patents & EXCLUSIVITIES
ABOUT THIS PAGE
